proxyvotesnow.com

Home › Companies › FATE THERAPEUTICS INC. › 2024-2025

FATE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and FATE THERAPEUTICS INC.’s Form 8-K, filed 2025-05-30 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 11Reported items
  • 145Asset managers
  • 1,528Fund votes
  • 2025-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore FATE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by FATE THERAPEUTICS INC.

These tallies are FATE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-30 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

FATE THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-05-29
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Dr. Shefali Agarwal 65,856,345---- 2,690,58819,634,302 Majority: yes
Elect Director: Bahram Valamehr, Ph.D., M.B.A. 67,859,201---- 687,73219,634,302 Majority: yes
Elect Director: Matthew C. Abernethy, M.B.A. 67,935,382---- 611,55119,634,302 Majority: yes
(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 87,110,990566,323503,922 --0 Majority: yes
(iii) Non-binding advisory vote on compensation of the Company's named executive officers. 63,041,9545,198,616306,363 --19,634,302 Majority: yes
(iv) Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers. 77,265,10710,557,548358,580 --0 Majority: yes
(vi) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. 51,379,95816,912,205254,770 --19,634,302 Majority: yes
(vii) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals. 72,616,99415,306,292257,949 --0 Majority: yes

Source: FATE THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-05-30 — read the filing on EDGAR.

How asset managers voted at the FATE THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 145 asset managers that disclosed a FATE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of FATE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes to approve the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 77,265,107AGAINST: 10,557,548

FATE THERAPEUTICS INC.’s own tally for this item (“(iv) Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.”): 77,265,107 for, 10,557,548 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 67% for, 9% against (77% of the company cast a for/against vote).

The 140 asset managers below cast 99.7% of the shares they voted on this item FOR (457,087 for, 1,058 against).

ONE YEAR 50.1%1 YEAR 47.0%
FOR: 457,087 (0.8%)AGAINST: 1,058 (0.0%)ABSTAIN: 36,918 (0.1%)ONE YEAR: 29,241,773 (50.1%)1 YEAR: 27,445,865 (47.0%)THREE YEARS: 1,131,115 (1.9%)3 YEARS: 21,030 (0.0%)1-YEAR: 300 (0.0%)1YEAR: 25 (0.0%)
Largest asset managers voting on “To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes ” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC00 001 Year
Vanguard00 00One Year
BlackRock00 001 Year
Citadel00 00One Year
JPMorgan00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Fidelity00 00One Year
ORBIMED ADVISORS LLC00 001 Year
JACOBS LEVY EQUITY MANAGEMENT, INC00 001 Year
Charles Schwab00 001 Year
Woodline Partners LP00 00One Year
Dimensional00 00Three Years
Vestal Point Capital, LP00 00One Year
State Street00 00One Year
Goldman Sachs00 001 Year
BRUCE FUND INC00 001 Year
Voya00 00One Year
DE Shaw00 00One Year
Northern Trust00 001 Year
Integral Health Asset Management, LLC412,1030 00For
Columbia Threadneedle00 00One Year
Nuveen00 00One Year
Two Sigma00 00One Year
TIAA00 00One Year
MELLON INVESTMENTS Corp00 00One Year

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 63,041,954AGAINST: 5,198,616

FATE THERAPEUTICS INC.’s own tally for this item (“(iii) Non-binding advisory vote on compensation of the Company's named executive officers.”): 63,041,954 for, 5,198,616 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 55% for, 5% against (60% of the company cast a for/against vote).

The 139 asset managers below cast 93% of the shares they voted on this item FOR (51,266,133 for, 3,931,025 against).

FOR 93%7%
FOR: 51,266,133 (92.8%)AGAINST: 3,931,025 (7.1%)ABSTAIN: 36,918 (0.1%)
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC12,872,9460 00For
Vanguard10,338,9820 00For
BlackRock7,158,780812 00For
Citadel3,273,6430 00For
GEODE CAPITAL MANAGEMENT, LLC2,269,6090 00For
Fidelity2,013,65956,494 00For
ORBIMED ADVISORS LLC01,680,580 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC1,536,0860 00For
Charles Schwab1,407,6500 00For
Woodline Partners LP1,370,1670 00For
Dimensional01,109,901 00Against
Vestal Point Capital, LP1,056,6550 00For
State Street998,054638 00For
Goldman Sachs832,3850 00For
BRUCE FUND INC550,0000 00For
Voya477,7440 00For
DE Shaw433,1920 00For
Northern Trust427,8190 00For
Integral Health Asset Management, LLC412,1030 00For
Columbia Threadneedle411,1540 00For
Nuveen378,3880 00For
Two Sigma344,8420 00For
TIAA328,3900 00For
MELLON INVESTMENTS Corp321,7310 00For
Lincoln Financial315,3256,190 00For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

3. TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%AGAINST 25%
FOR: 51,379,958AGAINST: 16,912,205

FATE THERAPEUTICS INC.’s own tally for this item (“(vi) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 51,379,958 for, 16,912,205 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 45% for, 15% against (60% of the company cast a for/against vote).

The 47 asset managers below cast 85% of the shares they voted on this item FOR (17,910,202 for, 3,233,415 against).

FOR 85%AGAINST 15%
FOR: 17,910,202 (84.6%)AGAINST: 3,233,415 (15.3%)ABSTAIN: 35,418 (0.2%)
Largest asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional01,013,439 00Against
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Integral Health Asset Management, LLC412,1030 00For
Columbia Threadneedle0411,154 00Against
Lincoln Financial0321,515 00Against
TIAA0310,798 00Against
Voya0238,872 00Against
Nationwide4,792203,417 00Against
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable16,815146,580 00Against
ETF Series Solutions0131,830 00Against
Brighthouse076,564 35,4180Against
Thrivent087,028 00Against
Invesco074,126 00Against
Prudential/PGIM49,10014,900 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock037,096 00Against

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

4. Election of Class III Directors: Dr. Bahram Valamehr

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 67,859,201WITHHELD: 687,732

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bahram Valamehr, Ph.D., M.B.A.”): 67,859,201 for, 687,732 withheld, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 59% for, 0.7% withheld (60% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (20,730,674 for, 0 against).

FOR 99.8%
FOR: 20,730,674 (99.8%)ABSTAIN: 35,418 (0.2%)
Largest asset managers voting on “Election of Class III Directors: Dr. Bahram Valamehr” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
Brighthouse76,5640 35,4180For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For
Russell Investments27,0530 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

5. Election of Class III Directors: Dr. Shefali Agarwal

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 65,856,345WITHHELD: 2,690,588

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Shefali Agarwal”): 65,856,345 for, 2,690,588 withheld, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 57% for, 2% withheld (60% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (20,186,766 for, 0 against).

FOR 97%
FOR: 20,186,766 (97.2%)ABSTAIN: 579,326 (2.8%)
Largest asset managers voting on “Election of Class III Directors: Dr. Shefali Agarwal” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial249,6610 71,8540For
TIAA310,7980 00For
Voya00 238,8720Abstain
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable16,8150 146,5800Abstain
ETF Series Solutions131,8300 00For
Brighthouse76,5640 35,4180For
Thrivent87,0280 00For
Invesco00 74,1260Abstain
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For
Russell Investments27,0530 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

6. Election of Class III Directors: Matthew C. Abernethy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 67,935,382WITHHELD: 611,551

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Matthew C. Abernethy, M.B.A.”): 67,935,382 for, 611,551 withheld, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 59% for, 0.6% withheld (60% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (20,730,674 for, 0 against).

FOR 99.8%
FOR: 20,730,674 (99.8%)ABSTAIN: 35,418 (0.2%)
Largest asset managers voting on “Election of Class III Directors: Matthew C. Abernethy” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
Brighthouse76,5640 35,4180For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For
Russell Investments27,0530 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

7. TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 87,110,990AGAINST: 566,323

FATE THERAPEUTICS INC.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 87,110,990 for, 566,323 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 76% for, 0.5% against (77% of the company cast a for/against vote).

The 45 asset managers below cast 99.9% of the shares they voted on this item FOR (20,730,253 for, 421 against).

FOR 99.8%
FOR: 20,730,253 (99.8%)AGAINST: 421 (0.0%)ABSTAIN: 35,418 (0.2%)
Largest asset managers voting on “TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE C” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
Brighthouse76,5640 35,4180For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For
Russell Investments27,0530 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

8. TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE ANY OF THE ABOVE PROPOSALS.

CORPORATE GOVERNANCEMajority of the votes cast: yes

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%
FOR: 72,616,994AGAINST: 15,306,292

FATE THERAPEUTICS INC.’s own tally for this item (“(vii) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.”): 72,616,994 for, 15,306,292 against, per its Form 8-K filed 2025-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 114,603,910 outstanding shares: 63% for, 13% against (77% of the company cast a for/against vote).

The 44 asset managers below cast 87% of the shares they voted on this item FOR (17,924,320 for, 2,793,349 against).

FOR 86%13%
FOR: 17,924,320 (86.4%)AGAINST: 2,793,349 (13.5%)ABSTAIN: 35,418 (0.2%)
Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEET” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional01,013,439 00Against
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle0411,154 00Against
Lincoln Financial243,47178,044 00For
TIAA0310,798 00Against
Voya0238,872 00Against
Nationwide4,792203,417 00Against
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions0131,830 00Against
Brighthouse076,564 35,4180Against
Thrivent087,028 00Against
Invesco74,1260 00For
Prudential/PGIM49,10014,900 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust038,377 00Against
John Hancock037,096 00Against
Russell Investments27,0530 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

9. TO APPROVE THE AMENDMENT OF OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 250,000,000 TO 350,000,000.

CAPITAL STRUCTURE

99.5% fund support · no official result

FOR 99.5%

The 44 asset managers below cast 99.5% of the shares they voted on this item FOR (20,668,569 for, 84,518 against).

FOR: 20,668,569 (99.6%)AGAINST: 84,518 (0.4%)
Largest asset managers voting on “TO APPROVE THE AMENDMENT OF OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED N” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
Brighthouse76,56435,418 00For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM14,90049,100 00Against
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For
Russell Investments27,0530 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

10. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (3,124,362 for, 0 against).

FOR: 3,124,362 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan3,103,9630 00For
GuideStone13,0050 00For
Jasper Ridge Partners, L.P.7,3940 00For

Showing the 10 reported items with the widest manager coverage, of 11 in total. View every item.

Largest FATE THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of FATE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 114,603,910 shares outstanding at the time of that meeting.

Top FATE THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Redmile Group, LLC 11.23%
2Vanguard 9.02%
3BlackRock 6.25%
4Citadel 2.86%
5JPMorgan 2.71%
6GEODE CAPITAL MANAGEMENT, LLC 1.98%
7Fidelity 1.81%
8ORBIMED ADVISORS LLC 1.47%
9JACOBS LEVY EQUITY MANAGEMENT, INC 1.34%
10Charles Schwab 1.23%

Reported FATE THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

FATE THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Redmile Group, LLC 15.91% 13D
Entities affiliated with Redmile Group, LLC 11.23% DEF14A
BlackRock 9.32% 13F
ARK Investment Management LLC 9.00% DEF14A
Vanguard Group 9.00% 13F
JPMorgan Chase 2.97% 13F
Dimensional Fund Advisors 2.26% 13F
Goldman Sachs 2.15% 13F
Geode Capital 1.98% 13F
Morgan Stanley 1.95% 13F

Percentages above are of 114,603,910 shares outstanding, as reported by FATE THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from FATE THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At FATE THERAPEUTICS INC.'s shareholder meeting held 2025-05-29, in the 2024-2025 proxy season, 145 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,528 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: FATE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-30.

FATE THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.